{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:40:59Z","timestamp":1787582459674,"version":"build-2736575974"},"reference-count":50,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antidepressant and anxiolytic medication use in people with dementia (PwD) may contribute to potentially inappropriate prescribing and be associated with mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate trends in prescribing of these medications and their association with mortality risk among PwD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A nested case-control study was conducted in Northern Ireland (NI) using linkage of five administrative population-based data sources within a cohort of dementia patients (identified if a medication indicated for dementia was prescribed). Dementia patients who died were matched to one control who lived at least as long as their matched case after dementia diagnosis (matched on age, sex and year of dementia). Exposure to antidepressant and anxiolytic medications was assessed from two years prior to study entry. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression after adjusting for demographic factors and comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 14,420 dementia cases. Antidepressants were prescribed to 59.2% of cases and 54.7% of controls while 44.8% of cases and 36.0% of controls were prescribed anxiolytics. There was evidence of a weak increased risk of mortality in PwD prescribed antidepressants (fully adjusted OR\u2009=\u20091.08; 95% CI 1.02\u20131.14) and a strong increased risk in those prescribed anxiolytics (fully adjusted OR\u2009=1.26; 95% CI 1.19\u20131.33) compared to nonusers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large NI population-based cohort of PwD, elevated levels of antidepressant and anxiolytic prescribing were observed. The use of anxiolytic medications was strongly associated with mortality in PwD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877251414888","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:05:54Z","timestamp":1768997154000},"page":"325-334","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Antidepressant and anxiolytic medications and risk of mortality in people with dementia: A nested case-control study in Northern Ireland"],"prefix":"10.1177","volume":"110","author":[{"given":"Catherine J.","family":"Sinnamon","sequence":"first","affiliation":[{"name":"School of Pharmacy, Queen's University Belfast, Belfast, Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel M.","family":"Hughes","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Queen's University Belfast, Belfast, Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris R.","family":"Cardwell","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9684-8182","authenticated-orcid":false,"given":"Heather E.","family":"Barry","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Queen's University Belfast, Belfast, Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"National Institute for Health and Care Excellence Dementia: assessment management and support for people living with dementia and their carers.https:\/\/www.nice.org.uk\/guidance\/ng97\/chapter\/recommendations#managing-non-cognitive-symptoms (2018 accessed 24 June 2025)."},{"key":"e_1_3_3_3_2","unstructured":"Alzheimer's Disease International. World Alzheimer\u2019s report Attitudes to dementia. https:\/\/www.alzint.org\/u\/WorldAlzheimerReport2019.pdf (2019 accessed 24 June 2025)."},{"key":"e_1_3_3_4_2","unstructured":"Prince M Knapp M Guerchet M et al. Dementia UK: Update (Second edition). [Research Report] King's College London. \u27e8hal-03516999\u27e9 (2014 accessed 24 June 2025)."},{"key":"e_1_3_3_5_2","unstructured":"Wittenberg R Hu B Barraza-Araiza L et al. Projections of older people living with dementia and costs of dementia care in the United Kingdom 2019\u20132040. https:\/\/www.lse.ac.uk\/cpec\/assets\/documents\/cpec-working-paper-5.pdf (2019 accessed 24 June 2025)."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2012.00073"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60240-2"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-020-4971-7"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.827660"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2012.09.027"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2015.08.014"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12630"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2017.07.001"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040622319853719"},{"key":"e_1_3_3_15_2","article-title":"Antidepressants for treating depression in dementia","volume":"4","author":"Bains J","year":"2002","unstructured":"Bains J, Birks J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev 2002; 4: CD003944.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_16_2","article-title":"Antidepressants for treating depression in dementia","volume":"8","author":"Dudas R","year":"2018","unstructured":"Dudas R, Malouf R, McCleery J, et al. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev 2018; 8: CD003944.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116114"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12828"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.3946"},{"key":"e_1_3_3_20_2","unstructured":"Northern Ireland Statistics and Research Agency. Registrar General Northern Ireland Annual Report 2023 https:\/\/www.nisra.gov.uk\/system\/files\/statistics\/RG%20Annual%20Report%202023.pdf (2024 accessed 11 August 2025)."},{"key":"e_1_3_3_21_2","unstructured":"Health and Social Care Business Services Organisation. Honest Broker Service Honest Broker Service - Business Services Organisation (BSO) Website (accessed 24 June 2025)."},{"key":"e_1_3_3_22_2","unstructured":"Health and Social Care Business Services Organisation. Researcher Access https:\/\/bso.hscni.net\/directorates\/digital\/honest-broker-service\/honest-broker-service-researcher-access\/ (Accessed 24 June 2025)."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1249-y"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-151177"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"e_1_3_3_26_2","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2025","unstructured":"Joint Formulary Committee. British National Formulary. London: BMJ Group and Pharmaceutical Press. 2025. https:\/\/bnf.nice.org.uk\/treatment-summary\/antidepressant-drugs.html (2025, accessed 24 June 2025)."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckt014"},{"key":"e_1_3_3_28_2","article-title":"Risk of depression in persons with Alzheimer's disease: a national cohort study","volume":"16","author":"Crump C","year":"2024","unstructured":"Crump C, Sieh W, Vickrey B, et al. Risk of depression in persons with Alzheimer's disease: a national cohort study. Alzheimers Dement 2024; 16: e12584.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610204000079"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610211000445"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.3018"},{"key":"e_1_3_3_32_2","article-title":"Antidepressant and antipsychotic prescribing in primary care for people with dementia","volume":"64","author":"Drummond N","year":"2018","unstructured":"Drummond N, McCleary L, Freiheit E, et al. Antidepressant and antipsychotic prescribing in primary care for people with dementia. Can Fam Physician 2018; 64: e488\u2013e497.","journal-title":"Can Fam Physician"},{"key":"e_1_3_3_33_2","article-title":"Antidepressants for agitation and psychosis in dementia","volume":"2","author":"Seitz DP","year":"2011","unstructured":"Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011; 2: CD008191.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2021.21"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.107631"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60830-1"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.14682"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4551"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61091-5"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21354"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.70185"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-000850"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14197119"},{"key":"e_1_3_3_44_2","first-page":"429","volume-title":"Goodman and Gilman\u2019s the pharmacological basis of therapeutics","author":"Baldessarini RJ","year":"2006","unstructured":"Baldessarini RJ. Drug therapy of depression and anxiety disorders. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman and Gilman\u2019s the pharmacological basis of therapeutics. New York: McGraw-Hill, 2006, pp.429\u2013460."},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18372"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1177\/1471301217746769"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1017\/S003329172200397X"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2017.02.022"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2015-206888"},{"key":"e_1_3_3_50_2","unstructured":"Duerden M Avery T Payne R. Polypharmacy and Medicines Optimisation: Making It Safe and Sound https:\/\/citeseerx.ist.psu.edu\/document?repid=rep1&type=pdf&doi=5b88d810fe7082d10f27190a7b1b29d0f2cb538f (2013 accessed 24 June 2025)."},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-190751"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251414888","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877251414888","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251414888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:10:06Z","timestamp":1777371006000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877251414888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/13872877251414888"],"URL":"https:\/\/doi.org\/10.1177\/13872877251414888","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}